

Zurampic

(lesinurad)



New Product
Slideshow

MPR

Introduction

- **Brand name:** Zurampic
- **Generic name:** Lesinurad
- **Pharmacological class:** URAT1 inhibitor
- **Strength and Formulation:** 200mg; tablets
- **Manufacturer:** Ironwood
- **How supplied:** Bottles—5, 30, 90
- **Legal Classification:** Rx

ZURAMPIC



Indications

- In combination with a xanthine oxidase inhibitor (including allopurinol or febuxostat), to treat **hyperuricemia associated with gout** in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone

Limitations of Use

- **Not** for treatment of asymptomatic hyperuricemia
- **Not** for use as monotherapy

Dosage & Administration

- Take in the AM with food and water
- 200mg once daily with a xanthine oxidase inhibitor
- Max 200mg daily
- Patients on daily allopurinol dose <300mg (or <200mg with eCLCr <60mL/min): not recommended

Considerations for Special Populations

- **Pregnancy:** No human data to inform a drug-associated risk
- **Nursing mothers:** Consider benefits and potential adverse effects
- **Pediatric:** <18yrs: not established
- **Geriatric:** No overall differences in safety or efficacy observed
- **Hepatic impairment:** Severe: not recommended
- **Renal impairment:** See Warnings/Precautions

Contraindications

- Severe renal impairment (eCLCr <30mL/min), ESRD, kidney transplant recipients, or dialysis patients
- Tumor lysis syndrome or Lesch-Nyhan syndrome

Warnings/Precautions

- Risk of acute renal failure when used without a xanthine oxidase inhibitor
- Assess renal function prior to initiation and periodically thereafter
- **Renal impairment** (eCLCr <45mL/min): do not initiate
- If eCLCr <60mL/min or with serum creatinine (SCr) elevations 1.5–2X pre-treatment value: monitor more frequently; if SCr >2X pre-treatment value: interrupt treatment

Warnings/Precautions

- Discontinue therapy if eCLCr is persistently $<45\text{mL/min}$
- Maintain adequate hydration (2 liters of liquid per day)
- Give gout flare prophylaxis
- Females should use additional non-hormonal methods of contraception

Interactions

- Caution with concomitant moderate CYP2C9 inhibitors (eg, fluconazole, amiodarone) and in CYP2C9 poor metabolizers
- Antagonized by moderate CYP2C9 inducers (eg, rifampin, carbamazepine), aspirin >325mg/day (in combination with allopurinol)

Interactions

- Antagonizes CYP3A substrates (eg, sildenafil, amlodipine)
- May affect sensitive CYP3A substrates (eg, HMG-CoA reductase inhibitors); monitor
- Concomitant epoxide hydrolase inhibitors (eg, valproic acid): not recommended
- May reduce efficacy of hormonal contraceptives

Adverse Reactions

- Headache
- Influenza
- Blood creatinine increase
- GERD
- Gout flares
- Renal events
- Cardiovascular events

Mechanism of Action

- Lesinurad reduces serum uric acid levels by inhibiting the function of transporter proteins involved in uric acid reabsorption in the kidney

Clinical Trials

- The efficacy of Zurampic 200mg and Zurampic 400mg once daily was studied in 3 multicenter, randomized, double-blind, placebo-controlled studies in adults with hyperuricemia and gout in combination with allopurinol or febuxostat; prophylaxis with colchicine or NSAIDs for the first 5 months of Zurampic therapy were given

Clinical Trials

- In **Study 1** (n=603) and **Study 2** (n=610), Zurampic 200mg with allopurinol was superior to allopurinol alone in lowering serum uric acid to <6mg/dL at Month 6
- In **Study 3**, gout patients with measurable tophi were randomized to Zurampic 200mg, Zurampic 400mg, or placebo in combination with febuxostat

Clinical Trials

- There was no statistical difference in the proportion of patients treated with Zurampic 200mg in combination with febuxostat achieving serum uric acid $<5\text{mg/dL}$ by Month 6 compared with febuxostat alone
- The rates of gout flare requiring treatment from Month 6 to 12 were not statistically different between Zurampic with allopurinol or febuxostat compared with allopurinol or febuxostat alone

Clinical Trials

- In Study 3, the proportion of patients who had complete resolution of ≥ 1 tophus did not statistically differ between Zurampic with febuxostat compared with febuxostat alone
- For more clinical trial data, see full labeling

New Product Monograph

- For more information view the product monograph available at:

<http://www.empr.com/zurampic/drug/34561/>